Multivariate Analysis of the Relationship Between Several Potential Prognostic Factors and the Probability of Leukemia-Related Events in the Total Group of Children With ALL and Within the Subgroup of Clinical Good PRD Responders
| Factor . | P Values . | |
|---|---|---|
| Total Group . | Only Clinical Good PRD Responders . | |
| Age (<2 or ≥10 yr v 2 to 9 yr) | .49 | .38 |
| BFM risk factor* (≥1.20 v <1.20) | .36 | .21 |
| Immunophenotype (pro-B/T-cell v common/pre-B) | .83 | .70 |
| DNA ploidy (nonhyperdiploid v hyperdiploid) | .63 | .97 |
| Clinical PRD response (poor v good) | .23 | — |
| In vitro PRD resistance (resistant vintermediately sensitive v highly sensitive) | .001 | .002 |
| Factor . | P Values . | |
|---|---|---|
| Total Group . | Only Clinical Good PRD Responders . | |
| Age (<2 or ≥10 yr v 2 to 9 yr) | .49 | .38 |
| BFM risk factor* (≥1.20 v <1.20) | .36 | .21 |
| Immunophenotype (pro-B/T-cell v common/pre-B) | .83 | .70 |
| DNA ploidy (nonhyperdiploid v hyperdiploid) | .63 | .97 |
| Clinical PRD response (poor v good) | .23 | — |
| In vitro PRD resistance (resistant vintermediately sensitive v highly sensitive) | .001 | .002 |
*Based on peripheral leukemic cell count and liver and spleen size.10